A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

NCT03448042 PHASE1 ACTIVE_NOT_RECRUITING

This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

Details

Lead sponsor	Genentech, Inc.
Phase	PHASE1
Status	ACTIVE_NOT_RECRUITING
Enrolment	123
Start date	Wed Jun 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Nov 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Solid Tumors

Interventions

• Runimotamab
• Trastuzumab
• Tocilizumab

Countries

Denmark, France, Italy, Japan, Netherlands, Belgium, Taiwan, United Kingdom, South Korea, Canada, Australia, Singapore, United States, Spain